About: Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation
Creator	Cooke, Kenneth Cooke, K Lazarus, H Lazarus, Hillard Salman, Huda Salman, H
Source	PMC
abstract	Although advances in antineoplastic therapy have considerably improved the survival of patients with hematological malignancies, current treatment modalities increase the risk of late complications. Several forms of chronic pulmonary dysfunction due to infectious or noninfectious causes commonly occur in the months to years after chemo-radiotherapy and can be fatal or result in long-term morbidity. The judicious use of prophylactic antimicrobial agents has tipped the balance toward noninfectious etiologies. Hence, while opportunistic infections still contribute to chronic lung disease, late sequelae resulting from antineoplastic therapy have been identified and reported. Patients who proceed to receive hematopoietic cell transplantation (HSCT) are particularly prone to developing lung complications. Pulmonary dysfunction occurring after HSCT may manifest with obstructive or restrictive pulmonary mechanics and may range in severity from subtle, subclinical functional changes to frank respiratory failure. Insights generated using animal models suggest that the immunologic mechanisms contributing to lung inflammation after HSCT may be similar to those responsible for graft-versus host disease. In sum, chronic fibrotic pulmonary dysfunction is a frequent and significant complication facing survivors of hematologic malignancies and their practitioners. The high incidence and suboptimal response to current support care and immunosuppressive therapy underscore the need for heightened awareness and continued research in this area.
has issue date	2010-08-19(xsd:dateTime)
bibo:doi	10.1007/978-3-642-15742-4_42
has license	no-cc
sha1sum (hex)	26ee9d86ae3b0353f8d5de6f5ce11a39810fca20
schema:url	https://doi.org/10.1007/978-3-642-15742-4_42
resource representing a document's title	Fibrosing Alveolitis in Hematologic Malignancy Patients Undergoing Hematopoietic Cell Transplantation
has PubMed Central identifier	PMC7123073
schema:publication	Pulmonary Involvement in Patients with Hematological Malignancies
resource representing a document's body	covid:26ee9d86ae3b0353f8d5de6f5ce11a39810fca20#body_text
is schema:about of	named entity 'consolidation' named entity 'conditioning' named entity 'hematopoietic cell' named entity 'tacrolimus' named entity 'man' named entity 'remission' named entity 'intravenously' named entity 'Contents' named entity 'LIVER' named entity 'YEAR' named entity 'liver' named entity 'day' named entity 'extensive' named entity 'de novo' named entity 'allogeneic' named entity 'hematopoietic cell' named entity 'idarubicin' named entity 'GVHD' named entity 'Hematopoietic Cell' named entity 'Hematologic Malignancy' named entity 'sibling' named entity 'alveolar' named entity 'pre-clinical' named entity 'pneumonitis' named entity 'Fungal infections' named entity 'chemotherapeutic agents' named entity 'GVHD' named entity 'HSCT' named entity 'GVHD' named entity 'chemotherapy-induced' named entity 'GVHD' named entity 'neutrophils' named entity 'noninfectious' named entity 'phase II' named entity 'rash' named entity 'bleomycin' named entity 'fibrotic' named entity 'DAD' named entity 'adenovirus' named entity 'prognosis' named entity 'viral infection' named entity 'fibrin' named entity 'chest wall' named entity 'pathology' named entity 'lung disease' named entity 'residual volume' named entity 'obstructive lung disease' named entity 'etoposide' named entity 'radiation-induced lung injury' named entity 'RLD' named entity 'obstructive lung disease' named entity 'bronchiolitis' named entity 'toxicity' named entity 'GVHD' named entity 'methotrexate' named entity 'Clinical symptoms' named entity 'cytostatic' named entity 'fibrosis' named entity 'cytotoxicity' named entity 'collagen' named entity 'radiation therapy' named entity 'lung function' named entity 'methotrexate' named entity 'phase III' named entity 'elastin' named entity 'chlorambucil' named entity 'FVC' named entity 'GVHD' named entity 'Histopathologic features' named entity 'alveolar epithelium' named entity 'lung physiology' named entity 'GVHD' named entity 'HSCT' named entity 'drug interactions' named entity 'asthma' named entity 'Organizing pneumonia' named entity 'allogeneic' named entity 'ACE inhibitors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software